Faron Pharmaceuticals Ltd (LON:FARN)

Faron Pharmaceuticals Ltd (LON:FARN)

Share Price
110.00 p
-7.5 (-6.38 %)
Market Cap
£40.96 m
Proactive Investors - Run By Investors For Investors

Faron Pharmaceuticals Ltd

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.

Market: AIM:FARN
52-week High/Low: 168.000p / 50.050p
Sector: Pharma & Biotech
Market Cap: £40.96 m
Website: www.faron.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Faron Pharmaceuticals Ltd

Faron Pharmaceuticals Ltd Timeline

Faron expects to receive the interim results from the INFORAAA study of Traumakine in the near future, allowing a full review of all the Traumakine data with key opinion leaders, after which Faron will make the final decisions on Traumakine's development.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use